Novartis has won FDA approval of Rhapsido (remibrutinib) as the first treatment specifically for symptomatic dermographism, a chronic hive condition triggered by stroking or scratching the skin. The Basel, Switzerland company announced the approval on 7 October 2026, extending a label that FDA first cleared for chronic spontaneous urticaria just over a year earlier, on 29.3% of patients reaching a complete hive response at Week 12 in the Phase 3 RemIND trial, against 14.0% on placebo.
A diagnosis made by stroking the skin
Symptomatic dermographism is a form of chronic inducible urticaria: a firm stroke or scratch raises a itchy, swollen wheal along the line of pressure within minutes, and in its symptomatic form the reaction is persistent and disruptive enough to count as a disease rather than a curiosity. Patients who do not respond adequately to H1 antihistamines — the usual first-line therapy — had no FDA-approved drug built for their condition specifically until Novartis’s 7 October 2026 approval.
Rhapsido (remibrutinib) is an oral Bruton’s tyrosine kinase (BTK) inhibitor, a class of drug that blocks a signaling enzyme inside mast cells and basophils — the cells that release histamine and drive a hive reaction. FDA first approved it in September 2025 for chronic spontaneous urticaria (CSU), a related but distinct condition in which hives appear without an obvious physical trigger. The two conditions can overlap in the same patient, but FDA’s SD approval covers symptomatic dermographism specifically, not chronic inducible urticaria as a category.
Three things this approval changes
The first SD-specific approval
No other drug carries an FDA indication built for symptomatic dermographism; physicians previously relied on off-label antihistamine escalation or off-label use of CSU therapies like omalizumab (Xolair).
Oral, not injectable
Rhapsido is a twice-daily pill. The closest approved comparator for related hive conditions, omalizumab, is an injectable biologic administered every two to four weeks.
Built on an existing safety record
Because Rhapsido already carries a CSU approval, the SD label expansion leans on a safety database FDA had already reviewed once, at the same 25 mg twice-daily dose, rather than starting from a blank safety file.
RemIND's dermographism cohort, in four figures
Figures from Novartis's 7 October 2026 announcement and the RemIND trial (NCT05976243).
Remibrutinib marks a “meaningful step forward” for symptomatic dermographism patients who remain inadequately controlled on H1 antihistamines alone. Giselle Mosnaim, M.D., lead investigator, RemIND trial — 7 October 2026 announcement
Twenty-nine percent against a twelve-week clock
RemIND was a 52-week, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 115 adults with symptomatic dermographism, randomizing them 1:1 to remibrutinib 25 mg twice daily or placebo for 24 weeks before an open-label extension. The primary endpoint — complete hive response on the Total Fric Score at Week 12 — was met: 29.3% on remibrutinib versus 14.0% on placebo, a difference the trial reported as statistically significant (P=0.0229), with responses appearing as early as Week 2. Through Week 24, the safety profile was reported as consistent with the drug's existing CSU experience, with nasopharyngitis, bleeding, headache, nausea and abdominal pain each occurring in at least 3% of patients.
A 71% non-response rate at Week 12 is also part of the record: most patients in the trial did not reach a complete response on remibrutinib by that measure, even though the drug cleared the statistical bar against placebo. Novartis's release does not report a later, higher response rate beyond Week 12 for the SD cohort specifically.
A Xolair-sized shadow over a smaller population
Remibrutinib is entering a category omalizumab (Xolair) has defined for over a decade. Xolair is not FDA-approved for symptomatic dermographism specifically, but physicians have used it off-label in refractory chronic inducible urticaria, including dermographism, drawing on its CSU approval. The Business Research Company sizes the broader chronic spontaneous urticaria drug market at $2.23 billion in 2025, rising to a projected $3.21 billion by 2030 — a market Rhapsido is now positioned to draw from on two fronts, CSU and SD, rather than one.
The chronic hive drug market Rhapsido competes in
$2.23B → $3.21B
Global chronic spontaneous urticaria drug market, 2025 to 2030, as reported by The Business Research Company.
Sources: The Business Research Company, Chronic Spontaneous Urticaria Global Market Report · DelveInsight, XOLAIR Market Size, Forecast, and Emerging Insight – 2032
Regulatory News outlook
We expect symptomatic dermographism to add a modest, high-single-digit share to remibrutinib's existing CSU patient base rather than open a large new market on its own; DelveInsight separately projects remibrutinib's total CSU-driven sales across the seven major markets to pass $1.5 billion by 2034.
How we got here: The Business Research Company's $2.23 billion 2025 CSU figure compounds to its own published $3.21 billion 2030 estimate at roughly 7.4% a year; we treat symptomatic dermographism as a label expansion onto the same drug and diagnostic pathway rather than a separately sized disease market, since no dermographism-specific market forecast has been published.
Rhapsido against symptomatic dermographism's other options
| Product | Company | Mechanism | SD status | Administration |
|---|---|---|---|---|
| Rhapsido (remibrutinib) | Novartis | Oral BTK inhibitor | FDA-approved, Oct 2026 (first for SD) | Oral, 25 mg twice daily |
| Xolair (omalizumab) | Genentech (US) | Anti-IgE monoclonal antibody | Approved for CSU; used off-label in SD | Injectable, every 2–4 weeks |
| High-dose H1 antihistamines | Multiple (generic) | H1 receptor antagonist | Standard first-line; many SD patients inadequately controlled | Oral, daily |
| Barzolvolimab (investigational) | Celldex Therapeutics | Anti-KIT monoclonal antibody | In clinical development; not approved | Injectable (investigational) |
From company labelling, announcements and public drug-approval records; not a clinical comparison.
From a 2025 first-in-class nod to a second indication
Rhapsido's road to a second approved indication
- 1996
Novartis formed
Created from the merger of Ciba-Geigy and Sandoz, headquartered in Basel, Switzerland.
- 30 September 2025
First CSU approval
FDA approved Rhapsido (remibrutinib) as the first oral, targeted BTK inhibitor for chronic spontaneous urticaria.
- 27 April 2026
EU approval for CSU
The European Commission approved Rhapsido as the first oral targeted treatment for chronic spontaneous urticaria in the EU.
- 12 June 2026
RemIND data presented
Novartis presented RemIND results at EAACI 2026, describing remibrutinib's potential across chronic inducible urticaria subtypes, including symptomatic dermographism.
- 7 October 2026
FDA approves the SD indication
FDA approved Rhapsido as the first treatment specifically for symptomatic dermographism, based on the RemIND trial's SD cohort.
- Ahead
Other subtypes and geographies
RemIND evaluated chronic inducible urticaria subtypes beyond symptomatic dermographism; Novartis has not disclosed a regulatory timeline for those or for an ex-US symptomatic dermographism filing.
What the antihistamine-failure population still needs
The approval is specifically bounded: it covers patients whose symptomatic dermographism is inadequately controlled by H1 antihistamines, not every person with the condition, and it does not extend to the other chronic inducible urticaria subtypes RemIND evaluated. A 29.3% complete-response rate at Week 12, while more than double the placebo rate, also means most trial patients had not reached that threshold by the primary endpoint — a detail worth weighing against the “first approved treatment” headline.
- Scope: the approval covers symptomatic dermographism inadequately controlled by H1 antihistamines, not chronic inducible urticaria broadly.
- Response bar: 29.3% of patients reached complete hive response at Week 12; a majority had not, by that specific measure.
- Geography: the 7 October 2026 announcement is a US approval; an ex-US regulatory timeline for the SD indication has not been disclosed.
Sources & further reading
- Novartis, “Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU),” press release, 7 October 2026. novartis.com
- AJMC, “FDA Approves First Symptomatic Dermographism Treatment.” ajmc.com
- HCPLive, “Remibrutinib Receives FDA Approval for Symptomatic Dermographism.” hcplive.com
- PracticalDermatology, “FDA Approves Remibrutinib as First Treatment for Symptomatic Dermographism.” practicaldermatology.com
- ClinicalTrials.gov, RemIND trial record (NCT05976243). clinicaltrials.gov
- U.S. Food and Drug Administration, Rhapsido (remibrutinib) prescribing information, NDA 218436. accessdata.fda.gov
- Novartis, “Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral targeted BTKi treatment for chronic spontaneous urticaria (CSU),” press release, 30 September 2025. novartis.com
- The Business Research Company, Chronic Spontaneous Urticaria Global Market Report. thebusinessresearchcompany.com
- DelveInsight, XOLAIR Market Size, Forecast, and Emerging Insight – 2032. delveinsight.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA approve for Novartis?
Rhapsido (remibrutinib) as the first FDA-approved treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, announced 7 October 2026. It expands Rhapsido's existing chronic spontaneous urticaria (CSU) approval from September 2025.
What data supported the approval?
The symptomatic dermographism cohort of the Phase 3 RemIND trial (NCT05976243), enrolling 115 adults. At Week 12, 29.3% of patients on remibrutinib reached a complete hive response on the Total Fric Score, versus 14.0% on placebo (P=0.0229), with responses seen as early as Week 2.
Is the dose different from the CSU indication?
No. Rhapsido is dosed at 25 mg orally twice daily for both chronic spontaneous urticaria and symptomatic dermographism, and the drug's safety profile through Week 24 in the SD cohort was consistent with its CSU experience.
Is this approval available outside the United States?
Not yet confirmed. Rhapsido holds European Commission approval for CSU (April 2026) and has completed regulatory submissions for CSU in multiple countries; Novartis's 7 October 2026 release covers the US approval for symptomatic dermographism specifically.
